The increased risk of microbial infections in multiple sclerosis patients: interplay between disease-modifying therapies and human phagocytes by Allizond, Valeria et al.
P0606 The increased risk of microbial infections in multiple sclerosis patients:
interplay between disease-modifying therapies and human phagocytes
Valeria Allizond1, Sara Scutera2, Rosaria Sparti*2, Paola Cavalla3, Tiziana Musso2, Anna Maria Cuffini1, Giuliana
Banche3
1 Bacteriology Laboratory, Department of Public Health and Pediatrics, University of Torino, Turin, Italy., 2
Immunology Laboratory, Department of Public Health and Pediatrics, University of Torino, Turin, Italy., 3
Department of Neuroscience, University of Torino, Turin, Italy.
Background: The risk infection in multiple sclerosis (MS) associated with MS treatments has become one of the
most important factors in the therapy choice. The hospitalization high rates and infection-related mortality could
be mainly attributed to disease-modifying therapy (DMT). DMT alters, at various extend, the innate immunity
against pathogens. In this project, granted by an ESCMID research grant, the straightforward effect of the most
common MS DMTs on healthy subject (HS) neutrophil functions was examined in vitro.
Materials/methods: To achieve this purpose HS polymorphonuclear cells (PMNs) were pre-treated with either
immunosuppressive ( i.e. natalizumab - NAT, fingolimod - FTY) or immunomodulatory ( i.e. interferonβ 1b – INFβ-
b, glatiramer acetate - GA) drugs, and then their functional activity was investigated. In detail, PMN intracellular
killing activity towards Klebsiella pneumoniae, the cytokine release profile, the apoptosis, the ROS production and
surface molecule expression were evaluated.
Results: In vitro assays with drug pre-treated HS PMNs showed a reduction in bacterial killing with statistically
significantly lower values (p<0.001) than those registered for the un-pre-treated controls for all the DMTs assayed
(Figure 1). In the same experimental conditions variable results, depending on the DMT used, for the other
examined neutrophil functions were achieved. The reduction in the intracellular killing activity of NAT pre-treated
PMNs was not accompanied by changes in the other functional parameters. On the contrary, this defective
neutrophil killing was also associated with a significantly lower ROS production, a slight increase of survival and
cytokine production with FTY pre-treatment, and with a lower cytokine release pattern in case of both INFβ-b and
GA pre-treatment.
Conclusions: As microbial killing is a PMN critical physiological function, involving various mechanisms and
although apoptosis, ROS, and cytokine do not seem to have an impact on the differences observed in the defective
killing capacity of PMNs from treated-MS patients, other mechanisms, due to PMN plasticity, might be involved.
However, our promising results regarding pre-treatment assays, confirmed that the PMN impairment is strongly
linked to the treatment itself and may contribute to increase exacerbations and microbial infection onset. The
balance of the overall risk versus benefit should be continuously re-evaluated during treatment.
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